

## AGENDA

### ALABAMA MEDICAID AGENCY PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

May 4, 2022  
1:00 p.m. – 3:00 p.m.

---

1. Opening remarks.....Chair
2. Approval of February 9, 2022 P&T Committee Meeting minutes.....Chair
3. Pharmacy program update.....Alabama Medicaid
4. Oral presentations by manufacturers/manufacturers’ representatives  
(prior to each respective class review)
5. Pharmacotherapy class re-reviews.....UMass Clinical Pharmacy Services
  - Mineralocorticoid (Aldosterone) Receptor Antagonists – AHFS 243220
  - Central Alpha-Agonists – AHFS 240816
  - Direct Vasodilators – AHFS 240820
  - Peripheral Adrenergic Inhibitors – AHFS 240832
  - Hypotensive Agents, Miscellaneous – AHFS 240892
  - Alpha-Adrenergic Blocking Agents – AHFS 242000
  - Beta-Adrenergic Blocking Agents – AHFS 242400
  - Dihydropyridines – AHFS 242808
  - Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892
  - Angiotensin-Converting Enzyme Inhibitors – AHFS 243204
  - Angiotensin II Receptor Antagonists – AHFS 243208
  - Renin Inhibitors – AHFS 243240
  - Loop Diuretics – AHFS 402808
  - Potassium-Sparing Diuretics – AHFS 402816
  - Thiazide Diuretics – AHFS 402820
  - Thiazide-Like Diuretics – AHFS 402824
  - Vasopressin Antagonists – AHFS 402828
  - Diuretics, Miscellaneous – AHFS 402892
  - Alzheimer’s Agents
    - *Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400* (current brands to be included: Aricept<sup>®</sup>, Exelon<sup>®</sup>, and Razadyne ER<sup>®</sup> only)
    - *Central Nervous System Agents, Miscellaneous – AHFS Class 289200* (current brands to be included: Aduhelm<sup>®</sup>, Namenda<sup>®</sup>, Namenda XR<sup>®</sup>, and Namzaric<sup>®</sup> only)
6. New Business
7. Results of voting announced.....Chair
8. Next meeting dates
  - August 10, 2022
  - November 9, 2022
  - February 8, 2023
  - May 3, 2023
9. Adjourn